Estrogen Receptors in Resistance to Hormone Therapy

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 608)


Estrogen and its receptors α and β (ERα and ERβ) play a major role in tumor progression and approximately two-thirds of breast cancers express these functional receptors. Thus, the ER is a major target for current and developing therapies. Although most ER-positive tumors initially respond to hormonal therapies such as tamoxifen, many tumors will eventually become resistant to tamoxifen induced growth inhibition. This chapter will discuss molecular mechanisms that contribute to hormonal resistance of current therapies including ERα mutations, the roles of proliferation and apoptosis in tumor homeostasis and receptor coregulator proteins. Additionally, the role of nonclassical ERα signaling through growth factor receptors and the subsequent downstream-initiated signaling, and the role of the progesterone receptors will be discussed.


Breast Cancer Estrogen Receptor Progesterone Receptor Hormone Resistance Tamoxifen Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 1998; 3(1):49–61.PubMedGoogle Scholar
  2. 2.
    Di Leo A, Messa C, Cavallini A et al. Estrogens and colorectal cancer. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1(1):1–12.PubMedGoogle Scholar
  3. 3.
    Pujol P, Rey JM, Nirde P et al. Differential expression of estrogen receptor-alpha and-beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998; 58(23):5367–5373.PubMedGoogle Scholar
  4. 4.
    Feigelson HS, Ross RK, Yu MC et al. Genetic susceptibility to cancer from exogenous and endogenous exposures. J Cell Biochem Suppl 1996; 25:15–22.PubMedGoogle Scholar
  5. 5.
    Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998; 90(11):814–823.PubMedGoogle Scholar
  6. 6.
    Beatson C. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 1896; 2:104–107.Google Scholar
  7. 7.
    Boyd S. On oophorectomy in cancer of the breast. Br Med J 1900; 2:1161–1167.Google Scholar
  8. 8.
    Jensen E, Jacobson HI. Fate of steroidal estrogens in target tissues. In: Pincus G, EP V, eds. Biological activities of steroids in relation to cancer. New York: Academic Press, 1960:161–174.Google Scholar
  9. 9.
    Jensen E, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962; 18:387–414.Google Scholar
  10. 10.
    Toft D, Gorski J. A receptor molecule for estrogens: Isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci USA 1966; 55(6):1574–1581.PubMedGoogle Scholar
  11. 11.
    Green S, Kumar V, Krust A et al. Structural and functional domains of the estrogen receptor. Cold Spring Harb Symp Quant Biol 1986; 51(Pt 2):751–758.PubMedGoogle Scholar
  12. 12.
    Green S, Walter P, Kumar V et al. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. Nature 1986; 320(6058):134–139.PubMedGoogle Scholar
  13. 13.
    Greene GL, Gilna P, Waterfield M et al. Sequence and expression of human estrogen receptor complementary DNA. Science 1986; 231(4742):1150–1154.PubMedGoogle Scholar
  14. 14.
    Walter P, Green S, Greene G et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 1985; 82(23):7889–7893.PubMedGoogle Scholar
  15. 15.
    Enmark E, Pelto-Huikko M, Grandien K et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82(12):4258–4265.PubMedGoogle Scholar
  16. 16.
    Mosselman S, Polman J, Dijkema R. ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392(1):49–53.PubMedGoogle Scholar
  17. 17.
    Ogawa S, Inoue S, Watanabe T et al. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 1998; 243(1):122–126.PubMedGoogle Scholar
  18. 18.
    Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001; 93(19):1449–1457.PubMedGoogle Scholar
  19. 19.
    Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002; 20(16):3386–3395.PubMedGoogle Scholar
  20. 20.
    Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20(16):3396–3403.PubMedGoogle Scholar
  21. 21.
    Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19(10):2596–2606.PubMedGoogle Scholar
  22. 22.
    Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18(22):3758–3767.PubMedGoogle Scholar
  23. 23.
    Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18(22):3748–3757.PubMedGoogle Scholar
  24. 24.
    Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002; 359(9324):2131–2139.PubMedGoogle Scholar
  25. 25.
    Kuiper GG, Enmark E, Pelto-Huikko M et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93(12):5925–5930.PubMedGoogle Scholar
  26. 26.
    Misrahi M, Atger M, d’Auriol L et al. Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochem Biophys Res Commun 1987; 143(2):740–748.PubMedGoogle Scholar
  27. 27.
    Steinmetz AC, Renaud JP, Moras D. Binding of ligands and activation of transcription by nuclear receptors. Annu Rev Biophys Biomol Struct 2001; 30:329–359.PubMedGoogle Scholar
  28. 28.
    Weatherman RV, Fletterick RJ, Scanlan TS. Nuclear-receptor ligands and ligand-binding domains. Annu Rev Biochem 1999; 68:559–581.PubMedGoogle Scholar
  29. 29.
    Tanenbaum DM, Wang Y, Williams SP et al. Crystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains. Proc Natl Acad Sci USA 1998; 95(11):5998–6003.PubMedGoogle Scholar
  30. 30.
    Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000; 14(2):121–141.PubMedGoogle Scholar
  31. 31.
    Shiau AK, Barstad D, Loria PM et al. The structural basis of estrogen receptor/ coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95(7):927–937.PubMedGoogle Scholar
  32. 32.
    Brzozowski AM, Pike AC, Dauter Z et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389(6652):753–758.PubMedGoogle Scholar
  33. 33.
    Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: Structure and function. Curr Opin Cell Biol 1998; 10(3):384–391.PubMedGoogle Scholar
  34. 34.
    Feng W, Ribeiro RC, Wagner RL et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998; 280(5370):1747–1749.PubMedGoogle Scholar
  35. 35.
    Shiau AK, Barstad D, Radek JT et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 2002; 9(5):359–364.PubMedGoogle Scholar
  36. 36.
    Pike AC, Brzozowski AM, Hubbard RE et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. Embo J 1999; 18(17):4608–4618.PubMedGoogle Scholar
  37. 37.
    Pike AC, Brzozowski AM, Walton J et al. Structural aspects of agonism and antagonism in the oestrogen receptor. Biochem Soc Trans 2000; 28(4):396–400.PubMedGoogle Scholar
  38. 38.
    Pike AC, Brzozowski AM, Walton J et al. Structural insights into the mode of action of a pure antiestrogen. Structure (Camb) 2001; 9(2):145–153.Google Scholar
  39. 39.
    Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17(5):1474–1481.PubMedGoogle Scholar
  40. 40.
    Fuqua SA, Schiff R, Parra I et al. Estrogen receptor beta protein in human breast cancer: Correlation with clinical tumor parameters. Cancer Res 2003; 63(10):2434–2439.PubMedGoogle Scholar
  41. 41.
    Speirs V, Parkes AT, Kerin MJ et al. Coexpression of estrogen receptor alpha and beta: Poor prognostic factors in human breast cancer? Cancer Res 1999; 59(3):525–528.PubMedGoogle Scholar
  42. 42.
    Jarvinen TA, Pelto-Huikko M, Holli K et al. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000; 156(1):29–35.PubMedGoogle Scholar
  43. 43.
    Speirs V, Kerin MJ. Prognostic significance of oestrogen receptor beta in breast cancer. Br J Surg 2000; 87(4):405–409.PubMedGoogle Scholar
  44. 44.
    Skliris GP, Carder PJ, Lansdown MR et al. Immunohistochemical detection of ERbeta in breast cancer: Towards more detailed receptor profiling? Br J Cancer 2001; 84(8):1095–1098.PubMedGoogle Scholar
  45. 45.
    Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998; 351(9114):1451–1467.Google Scholar
  46. 46.
    Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988; 15(2 Suppl 1):20–25.PubMedGoogle Scholar
  47. 47.
    Knight WA, Livingston RB, Gregory EJ et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977; 37(12):4669–4671.PubMedGoogle Scholar
  48. 48.
    Katzenellenbogen BS, Montano MM, Ediger TR et al. Estrogen receptors: Selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res 2000; 55:163–193, (discussion 194–165).PubMedGoogle Scholar
  49. 49.
    Montano MM, Ekena K, Krueger KD et al. Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 1996; 10(3):230–242.PubMedGoogle Scholar
  50. 50.
    Endoh H, Maruyama K, Masuhiro Y et al. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Mol Cell Biol 1999; 19(8):5363–5372.PubMedGoogle Scholar
  51. 51.
    McKenna NJ, Lanz RB, O’Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 1999; 20(3):321–344.PubMedGoogle Scholar
  52. 52.
    Dotzlaw H, Leygue E, Watson PH et al. Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res 1999; 59(3):529–532.PubMedGoogle Scholar
  53. 53.
    Knowlden JM, Hutcheson IR, Jones HE et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144(3):1032–1044.PubMedGoogle Scholar
  54. 54.
    Hopp T, Weiss H, Parra I et al. Low levels of estrogen receptor beta protein predicts resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004; 10(22).Google Scholar
  55. 55.
    Mann S, Laucirica R, Carlson N et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 2001; 32(1):113–118.PubMedGoogle Scholar
  56. 56.
    Iwase H, Zhang Z, Omoto Y et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol 2003; 52(Suppl 1):S34–38.Google Scholar
  57. 57.
    Esslimani-Sahla M, Simony-Lafontaine J, Kramar A et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004; 10(17):5769–5776.PubMedGoogle Scholar
  58. 58.
    Roodi N, Bailey LR, Kao WY et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995; 87(6):446–451.PubMedGoogle Scholar
  59. 59.
    Herynk MH, Euqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004.Google Scholar
  60. 60.
    Karnik PS, Kulkarni S, Liu XP et al. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994; 54(2):349–353.PubMedGoogle Scholar
  61. 61.
    Graham IInd ML, Krett NL, Miller LA et al. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res 1990; 50(19):6208–6217.PubMedGoogle Scholar
  62. 62.
    Zhang QX, Borg A, Wolf DM et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997; 57(7):1244–1249.PubMedGoogle Scholar
  63. 63.
    Jiang SY, Langan-Fahey SM, Stella AL et al. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol Endocrinol 1992; 6(12):2167–2174.PubMedGoogle Scholar
  64. 64.
    Ince BA, Schodin DJ, Shapiro DJ et al. Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors. Endocrinology 1995; 136(8):3194–3199.PubMedGoogle Scholar
  65. 65.
    Fuqua SA, Wiltschke C, Zhang QX et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 2000; 60(15):4026–4029.PubMedGoogle Scholar
  66. 66.
    Soulez M, Parker MG. Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling. J Mol Endocrinol 2001; 27(3):259–274.PubMedGoogle Scholar
  67. 67.
    Hayashi SI, Eguchi H, Tanimoto K et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 2003; 10(2):193–202.PubMedGoogle Scholar
  68. 68.
    Coser KR, Chesnes J, Hur J et al. Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc Natl Acad Sci USA 2003; 100(24):13994–13999.PubMedGoogle Scholar
  69. 69.
    Hodges LC, Cook JD, Lobenhofer EK et al. Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res 2003; 1(4):300–311.PubMedGoogle Scholar
  70. 70.
    Gompel A, Somai S, Chaouat M et al. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000; 65(10–11):593–598.PubMedGoogle Scholar
  71. 71.
    Kumar R, Mandal M, Lipton A et al. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 1996; 2(7):1215–1219.PubMedGoogle Scholar
  72. 72.
    Treeck O, Zhou R, Diedrich K et al. Tamoxifen long-term treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells. Anticancer Drugs 2004; 15(8):787–793.PubMedGoogle Scholar
  73. 73.
    Stendahl M, Kronblad A, Ryden L et al. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004; 90(10):1942–1948.PubMedGoogle Scholar
  74. 74.
    Zhou Q, Hopp T, Fuqua SA et al. Cyclin D1 in breast premalignancy and early breast cancer: Implications for prevention and treatment. Cancer Lett 2001; 162(1):3–17.PubMedGoogle Scholar
  75. 75.
    McMahon C, Suthiphongchai T, DiRenzo J et al. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA 1999; 96(10):5382–5387.PubMedGoogle Scholar
  76. 76.
    Lamb J, Ladha MH, McMahon C et al. Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 2000; 20(23):8667–8675.PubMedGoogle Scholar
  77. 77.
    Zwijsen RM, Wientjens E, Klompmaker R et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997; 88(3):405–415.PubMedGoogle Scholar
  78. 78.
    Bautista S, Valles H, Walker RL et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 1998; 4(12):2925–2929.PubMedGoogle Scholar
  79. 79.
    Kurebayashi J, Otsuki T, Kunisue H et al. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 2000;6(2):512–518.PubMedGoogle Scholar
  80. 80.
    Murphy LC, Simon SL, Parkes A et al. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res 2000; 60(22):6266–6271.PubMedGoogle Scholar
  81. 81.
    Murphy LC, Leygue E, Niu Y et al. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 2002; 87(12):1411–1416.PubMedGoogle Scholar
  82. 82.
    Smith CL, Nawaz Z, O’Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11(6):657–666.PubMedGoogle Scholar
  83. 83.
    Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295(5564):2465–2468.PubMedGoogle Scholar
  84. 84.
    Jepsen K, Hermanson O, Onami TM et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 2000; 102(6):753–763.PubMedGoogle Scholar
  85. 85.
    Anzick SL, Kononen J, Walker RL et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277(5328):965–968.PubMedGoogle Scholar
  86. 86.
    List HJ, Reiter R, Singh B et al. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 2001; 68(1):21–28.PubMedGoogle Scholar
  87. 87.
    Louie MC, Zou JX, Rabinovich A et al. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 2004; 24(12):5157–5171.PubMedGoogle Scholar
  88. 88.
    Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95(5):353–361.PubMedGoogle Scholar
  89. 89.
    Girault I, Lerebours F, Amarir S et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: Evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 2003; 9(4):1259–1266.PubMedGoogle Scholar
  90. 90.
    Graham JD, Bain DL, Richer JK et al. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?. J Steroid Biochem Mol Biol 2000; 74(5):255–259.PubMedGoogle Scholar
  91. 91.
    Lavinsky RM, Jepsen K, Heinzel T et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 1998; 95(6):2920–2925.PubMedGoogle Scholar
  92. 92.
    Shang Y, Hu X, DiRenzo J et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000; 103(6):843–852.PubMedGoogle Scholar
  93. 93.
    Zhang X, Jeyakumar M, Petukhov S et al. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol Endocrinol 1998; 12(4):513–524.PubMedGoogle Scholar
  94. 94.
    Jackson TA, Richer JK, Bain DL et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997; 11(6):693–705.PubMedGoogle Scholar
  95. 95.
    Morrison AJ, Herrera RE, Heinsohn EC et al. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol 2003; 17(8):1543–1554.PubMedGoogle Scholar
  96. 96.
    Kraus WL, Weis KE, Katzenellenbogen BS. Determinants for the repression of estrogen receptor transcriptional activity by ligand-occupied progestin receptors. J Steroid Biochem Mol Biol 1997; 63(4–6):175–188.PubMedGoogle Scholar
  97. 97.
    Le Goff P, Montano MM, Schodin DJ et al. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 1994; 269(6):4458–4466.PubMedGoogle Scholar
  98. 98.
    Rogatsky I, Trowbridge JM, Garabedian MJ. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem 1999; 274(32):22296–22302.PubMedGoogle Scholar
  99. 99.
    Liu H, Lee ES, Deb Los Reyes A et al. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res 2001; 61(9):3632–3639.PubMedGoogle Scholar
  100. 100.
    Karas RH, Gauer EA, Bieber HE et al. Growth factor activation of the estrogen receptor in vascular cells occurs via a mitogen-activated protein kinase-independent pathway. J Clin Invest 1998; 101(12):2851–2861.PubMedGoogle Scholar
  101. 101.
    Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270(5241):1491–1494.PubMedGoogle Scholar
  102. 102.
    Bunone G, Briand PA, Miksicek RJ et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. Embo J 1996; 15(9):2174–2183.PubMedGoogle Scholar
  103. 103.
    Ali S, Metzger D, Bornert JM et al. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. Embo J 1993; 12(3):1153–1160.PubMedGoogle Scholar
  104. 104.
    Joel PB, Smith J, Sturgill TW et al. pp90 rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 1998; 18(4):1978–1984.PubMedGoogle Scholar
  105. 105.
    Joel PB, Traish AM, Lannigan DA. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 1998; 273(21):13317–13323.PubMedGoogle Scholar
  106. 106.
    Castano E, Chen CW, Vorojeikina DP et al. The role of phosphorylation in human estrogen receptor function. J Steroid Biochem Mol Biol 1998; 65(1–6):101–110.PubMedGoogle Scholar
  107. 107.
    Clark DE, Poteet-Smith CE, Smith JA et al. Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. Embo J 2001; 20(13):3484–3494.PubMedGoogle Scholar
  108. 108.
    Sun M, Paciga JE, Feldman RI et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 2001; 61(16):5985–5991.PubMedGoogle Scholar
  109. 109.
    Arnold SF, Obourn JD, Jaffe H et al. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol 1994; 8(9):1208–1214.PubMedGoogle Scholar
  110. 110.
    Chen D, Pace PE, Coombes RC et al. Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 1999; 19(2):1002–1015.PubMedGoogle Scholar
  111. 111.
    Michalides R, Griekspoor A, Balkenende A et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004; 5(6):597–605.PubMedGoogle Scholar
  112. 112.
    Arnold SF, Obourn JD, Jaffe H et al. Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol 1995; 9(1):24–33.PubMedGoogle Scholar
  113. 113.
    Carlson KE, Choi I, Gee A et al. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: Evidence that an open pocket conformation is required for ligand interaction. Biochemistry 1997; 36(48):14897–14905.PubMedGoogle Scholar
  114. 114.
    Skafar DF. Formation of a powerful capping motif corresponding to start of “helix 12” in agonist-bound estrogen receptor-alpha contributes to increased constitutive activity of the protein. Cell Biochem Biophys 2000; 33(1):53–62.PubMedGoogle Scholar
  115. 115.
    Weis KE, Ekena K, Thomas JA et al. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 1996; 10(11):1388–1398.PubMedGoogle Scholar
  116. 116.
    Zhong L, Skafar DF. Mutations of tyrosine 537 in the human estrogen receptor-alpha selectively alter the receptor’s affinity for estradiol and the kinetics of the interaction. Biochemistry 2002; 41(13):4209–4217.PubMedGoogle Scholar
  117. 117.
    Schlegel A, Wang C, Katzenellenbogen BS et al. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J Biol Chem 1999; 274(47):33551–33556.PubMedGoogle Scholar
  118. 118.
    Newby JC, Johnston SR, Smith IE et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997; 3(9):1643–1651.PubMedGoogle Scholar
  119. 119.
    Hutcheson IR, Knowlden JM, Madden TA et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 2003; 81(1):81–93.PubMedGoogle Scholar
  120. 120.
    Nicholson RI, Gee JM, Knowlden J et al. The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 2003; 80(Suppl 1):S29–34, (discussion S35).Google Scholar
  121. 121.
    Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER 2/neu. Breast Cancer Res Treat 1993; 24(2):85–95.Google Scholar
  122. 122.
    Ropero S, Menendez JA, Vazquez-Martin A et al. Trastuzumab plus tamoxifen: Anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 2004; 86(2):125–137.PubMedGoogle Scholar
  123. 123.
    Moulder SL, Yakes FM, Muthuswamy SK et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD 1839 (Iressa) inhibits HEr2/neu (erb B2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61(24):8887–8895.PubMedGoogle Scholar
  124. 124.
    Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96(12):926–935.PubMedGoogle Scholar
  125. 125.
    Kurokawa H, Lenferink AE, Simpson JF et al. Inhibition of HER2/neu (erb B-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60(20):5887–5894.PubMedGoogle Scholar
  126. 126.
    Fleming FJ, Myers E, Kelly G et al. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol 2004; 57(10):1069–1074.PubMedGoogle Scholar
  127. 127.
    Castoria G, Barone MV, Di Domenico M et al. Nontranscriptional action of oestradiol and progestin triggers DNA synthesis. Embo J 1999; 18(9):2500–2510.PubMedGoogle Scholar
  128. 128.
    Santen RJ, Song RX, McPherson R et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002; 80(2):239–256.PubMedGoogle Scholar
  129. 129.
    Oh AS, Lorant LA, Holloway JN et al. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001; 15(8):1344–1359.PubMedGoogle Scholar
  130. 130.
    Gee JM, Robertson JF, Ellis IO et al. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95(4):247–254.PubMedGoogle Scholar
  131. 131.
    Atanaskova N, Keshamouni VG, Krueger JS et al. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 2002; 21(25):4000–4008.PubMedGoogle Scholar
  132. 132.
    Driggers PH, Segars JH. Estrogen action and cytoplasmic signaling pathways. Part II: The role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 2002; 13(10):422–427.PubMedGoogle Scholar
  133. 133.
    Campbell RA, Bhat-Nakshatri P, Patel NM et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 2001; 276(13):9817–9824.PubMedGoogle Scholar
  134. 134.
    Faridi J, Wang L, Endemann G et al. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 2003; 9(8):2933–2939.PubMedGoogle Scholar
  135. 135.
    Shoman N, Klassen S, McFadden A et al. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 2004.Google Scholar
  136. 136.
    Cho H, Katzenellenbogen BS. Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. Mol Endocrinol 1993; 7(3):441–452.PubMedGoogle Scholar
  137. 137.
    Bocquel MT, Kumar V, Stricker C et al. The contribution of the N-and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. Nucleic Acids Res 1989; 17(7):2581–2595.PubMedGoogle Scholar
  138. 138.
    Tzukerman MT, Esty A, Santiso-Mere D et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994; 8(1):21–30.PubMedGoogle Scholar
  139. 139.
    McDonnell DP, Clemm DL, Hermann T et al. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995; 9(6):659–669.PubMedGoogle Scholar
  140. 140.
    Fujita T, Kobayashi Y, Wada O et al. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells. J Biol Chem 2003; 278(29):26704–26714.PubMedGoogle Scholar
  141. 141.
    Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140(12): 5566–5578.PubMedGoogle Scholar
  142. 142.
    McInerney EM, Weis KE, Sun J et al. Transcription activation by the, human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 1998; 139(11):4513–4522.PubMedGoogle Scholar
  143. 143.
    Hyder SM, Chiappetta C, Stancel GM. Interaction of human estrogen receptors alpha and beta with the same naturally occurring estrogen response elements. Biochem Pharmacol 1999; 57(6):597–601.PubMedGoogle Scholar
  144. 144.
    Delaunay F, Pettersson K, Tujague M et al. Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 2000; 58(3):584–590.PubMedGoogle Scholar
  145. 145.
    Cowley SM, Parker MG. A comparison of transcriptional activation by ER alpha and ER beta. J Steroid Biochem Mol Biol 1999; 69(1–6):165–175.PubMedGoogle Scholar
  146. 146.
    Wissink S, van der Burg B, Katzenellenbogen BS et al. Synergistic activation of the serotonin-1A receptor by nuclear factor-kappa B and estrogen. Mol Endocrinol 2001; 15(4):543–552.PubMedGoogle Scholar
  147. 147.
    Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277(5331):1508–1510.PubMedGoogle Scholar
  148. 148.
    Webb P, Lopez GN, Uht RM et al. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estorgen-like effects of antiestrogens. Mol Endocrinol 1995; 9(4):443–456.PubMedGoogle Scholar
  149. 149.
    Saville B, Wormke M, Wang F et al. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (SP1) promoter elements. J Biol Chem 2000; 275(8):5379–5387.PubMedGoogle Scholar
  150. 150.
    Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001; 62:231–252.PubMedGoogle Scholar
  151. 151.
    Gelbfish GA, Davidson AL, Kopel S et al. Relationship of estrogen and progesterone receptors to prognosis in breast cancer. Ann Surg 1988; 207(1):75–79.PubMedGoogle Scholar
  152. 152.
    Stonelake PS, Baker PG, Gillespie WM et al. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 1994; 30A(1):5–11.PubMedGoogle Scholar
  153. 153.
    Clark GM, McGuire WL, Hubay CA et al. The importance of estrogen and progesterone receptor in primary breast cancer. Prog Clin Biol Res 1983; 132E:183–190.PubMedGoogle Scholar
  154. 154.
    Bardou VJ, Arpino G, Elledge RM et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003; 21(10):1973–1979.PubMedGoogle Scholar
  155. 155.
    Dowsett M. Analysis of time to recurrence in the ATAC (armidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Paper presented at: San Antonio Breast Cancer Symposium, 2003: San Antonio.Google Scholar
  156. 156.
    Fuqua SA, Cui Y, Lee AV et al. Insights into the role of progesterone receptors in breast cancer. Journal of Clinical Oncology 2005; 23(4).Google Scholar
  157. 157.
    Hopp TA, Weiss HL, Hilsenbeck SG et al. Breast cancer patients with progesterone receptor PR-A-Rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004; 10(8):2751–2760.PubMedGoogle Scholar
  158. 158.
    Vegeto E, Shahbaz MM,. Wen DX et al. HUman progesterone receptor A form is a cell-and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993; 7(10):1244–1255.PubMedGoogle Scholar
  159. 159.
    Wen DX, Xu YF, Mais DE et al. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 1994; 14(12):8356–8364.PubMedGoogle Scholar
  160. 160.
    McDonnell DP, Shahbaz MM, Vegeto E et al. The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. J Steroid Biochem Mol Biol 1994; 48(5–6):425–432.PubMedGoogle Scholar
  161. 161.
    Kraus WL, Weis KE, Katzenellenbogen BS. Inhibitory cross-talk between steroid hormone receptors: Differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist-and antagonist-occupied progestin receptors. Mol Cell Biol 1995; 15(4):1847–1857.PubMedGoogle Scholar
  162. 162.
    Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogne receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19(18):3808–3816.PubMedGoogle Scholar
  163. 163.
    Ma XJ, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5(6):607–616.PubMedGoogle Scholar
  164. 164.
    van’ t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415(6871):530–536.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  1. 1.Breast CenterBaylor College of MedicineHoustonUSA

Personalised recommendations